Dr. Pranitha V. Prodduturvar, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 103
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
AL license MD.37066 · GA license 101698 · MN license 67420 -
Hospice and Palliative Medicine (Internal Medicine) Physician
NE license 26148 -
Hospitalist Physician
NE license 26148 -
Internal Medicine Physician
NE license 26148
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northside Hospital Atlanta, GA
- Northside Hospital Forsyth Cumming, GA
- Northside Hospital Gwinnett Lawrenceville, GA
- Northside Hospital Duluth Duluth, GA
Medical groups
- North Atlanta Oncology Services LLC (29 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 103
- Services billed
- 303
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 187 | 71 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 35 | 20 |
| New patient office or other outpatient visit, 60-74 minutes | 25 | 25 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 22 | 22 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 15 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Mobile, AL | 35 |
| Tagrisso (osimertinib mesylate) | 33 |
| Gabapentin Other prescribers in Mobile, AL | 32 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Mobile, AL | 23 |
| Letrozole Other prescribers in Mobile, AL | 20 |
| Ondansetron Hcl Other prescribers in Mobile, AL | 19 |
| Oxycodone Hcl Other prescribers in Mobile, AL | 13 |
| Pantoprazole Sodium Other prescribers in Mobile, AL | 13 |
| Prednisone Other prescribers in Mobile, AL | 12 |
| Lorazepam Other prescribers in Mobile, AL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 51 payments worth $1,037 in total to this clinician.
| Merck Sharp & Dohme LLC | $107 |
|---|---|
| Pfizer Inc. | $103 |
| AstraZeneca Pharmaceuticals LP | $100 |
| Seagen Inc. | $99.00 |
| Daiichi Sankyo Inc. | $91.62 |
| Incyte Corporation | $78.57 |
| Genentech USA, Inc. | $48.49 |
| Syndax Pharmaceuticals, Inc. | $44.92 |
| Food and Beverage | $909 |
|---|---|
| Education | $128 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Seagen Inc. Apr 3, 2025 | Education in-kind | $99.00 |
| Pfizer Inc. Sep 19, 2025 | Education TUKYSA · ONCOLOGY · in-kind | $16.01 |
| Pfizer Inc. Feb 5, 2025 | Education BRAFTOVI; MEKTOVI · ONCOLOGY · in-kind | $13.04 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $36,268 in research payments for these studies, mostly to the institutions running them.
- SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negativ…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.